Table 3 Multivariate age-adjusted progression-free survival and overall survival.

From: Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

 

Variable

n/N (%)

PFS

OS

   

HR (95% CI)

P-value

HR (95% CI)

P-value

Multivariate

RVd arm

235/460 (51%)

0.77 (0.62, 0.95)

0.013

0.75 (0.58, 0.98)

0.033

 

ISS Stage III

155/460 (34%)

1.34 (1.01, 1.77)

0.041

1.98 (1.38, 2.86)

<.001

 

ISS Stage II

179/460 (39%)

1.12 (0.86, 1.47)

0.398

1.36 (0.95, 1.97)

0.096

 

Intent to Transplant

315/460 (68%)

0.95 (0.74, 1.23)

0.714

0.73 (0.54, 0.99)

0.043

 

Age > =65 yr

197/460 (43%)

1.27 (1.00, 1.61)

0.048

1.63 (1.21, 2.19)

0.001

  1. HR—hazard ratio, 95% CI—95% confidence interval, P-value from score Chi-square test in Cox regression.
Back to article page